Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: The Biopharmaceutical Contract ...

The Hong Kong stock market has finished lower in four straight sessions, retreating more than 520 points or 2.8 percent along the ...

连续第二年被纳入道琼斯可持续发展指数，彰显可持续发展领导力引领绿色生物药发展，技术创新赋能健康未来 上海2025年1月2日 /美通社/ -- 全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, ...

根据AI大模型测算海利生物后市走势。短期趋势看，连续3日被主力资金减仓。主力轻度控盘。中期趋势方面，上方有一定套牢筹码积压。近期该股有吸筹现象，但吸筹力度不强。舆情分析来看，目前市场情绪极度悲观。

Role of Real-World Evidence (RWE) in Driving Pharmaceutical R&D Outsourcing Market Growth ...

Whether you’re a fan of the All Blacks, a follower of the women’s game or someone who watches every phase of play in the Premiership, our rugby features and news pieces will provide you with all of ...